Neurotrope BioScience completes $9.1mm Series A round; adds more funds to close round at $21.9mm

Neurotrope BioScience Inc. (medicines and diagnostics for neurodegenerative disorders) raised $9.1mm in its Series A financing from 26 undisclosed investors. The 2012 start-up sold 9.1mm shares of Series A convertible preferred stock for $1.00. Neurotrope is beginning operations with worldwide rights to diagnostic and therapeutic technologies from the Blanchette Rockefeller Neurosciences Institute. The biotech hopes to launch in 2014 an early-stage AD detection test based on inflammation signaling in skin fibroblasts, followed four years later by an AD drug that activates protein kinase C-epsilon.